ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the ...

(RTTNews) - Abbott (ABT) announced the company's next-generation FreeStyle Libre 2 integrated continuous glucose monitoring system is now available to Medicare patients. It is now accessible to all ...

- U.S. Centers for Medicare & Medicaid Services (CMS) reimbursement expands access of the FreeStyle Libre 2 system to Medicare patients[1] to better manage their diabetes - The FreeStyle Libre 2 ...

First and only continuous glucose monitoring system to be nationally reimbursed in France for people who use once-daily (basal) insulin 1 Expanded reimbursement facilitates wider access to continuous ...

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...

A new study published in US Endocrinology found Abbott’s continuous glucose monitoring system, the FreeStyle Libre, demonstrated significant cost savings for diabetic care compared to traditional ...

Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...

People living with diabetes now have the option to use Abbott’s next-generation FreeStyle Libre 2, an integrated continuous glucose monitor. Abbott received the Food and Drug Administration’s ...

Abbott’s FreeStyle Libre glucose sensor has already been proven to help people with both Type 1 and Type 2 diabetes better manage their blood sugar levels, and a new study demonstrates just how ...

Abbott’s continuous glucose monitoring system, the FreeStyle Libre 2, has been approved in Canada for adults and children four years and older with diabetes. The FreeStyle Libre 2 system continuously ...

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...